Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report by Sprinzl, Martin F et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Cancer
Open Access Case report
Gemcitabine in combination with EGF-Receptor antibody 
(Cetuximab) as a treatment of cholangiocarcinoma: a case report
Martin F Sprinzl*1, Carl C Schimanski†1, Markus Moehler†1, 
Simin Schadmand-Fischer†2, Peter R Galle†1 and Stephan Kanzler†1
Address: 1I. Department of Medicine, Johannes-Gutenberg University, Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany and 2Department of 
Radiology, Johannes-Gutenberg University, Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany
Email: Martin F Sprinzl* - sprinzl@1-med.klinik.uni-mainz.de; Carl C Schimanski - schimanski@1-med.klinik.uni-mainz.de; 
Markus Moehler - moehler@1-med.klinik.uni-mainz.de; Simin Schadmand-Fischer - schadman@radiologie.klinik.uni-mainz.de; 
Peter R Galle - galle@mail.uni-mainz.de; Stephan Kanzler - kanzler@mail.uni-mainz.de
* Corresponding author    †Equal contributors
Abstract
Background: Extensive disease of cholangiocarcinoma (CC) determines the overall outcome and
limits curative resection. Despite chemotherapy, which has been introduced to improve the
outcome of biliary tract malignancies, the benefit in survival is still marginal.
Case presentation: We report a 69-year-old patient with non-resectable CC showing hepatic
metastasis and peritoneal carcinomatosis. Diagnosis was based on computed tomography, mini-
laparoscopy and bioptic specimens. Histology revealed an adenocarcinoma of the biliary tract with
expression of epithelial growth factor receptor. After informed consent the patient received
experimental gemcitabine (1000 mg/m2) every other week and cetuximab (250 mg/m2) weekly for
palliative chemotherapy. During the reported follow up (since time of first presentation) 20 cycles
of chemotherapy were administered. Relevant chemotherapy-related toxicity was limited on
gemcitabine-associated side effects. Predominantly, haematological toxicity (CTC, grade 3) and
neutropenic fever (CTC, grade 3) promoted by catheter-related sepsis were observed. Cetuximab
caused only mild skin toxicity (CTC, grade 1).
Chemotherapy led to a partial response (> 30% reduction, according to RECIST) of the target
lesions and disappearance of the peritoneal carcinomatosis as shown by computed tomography.
Partial response occurred after 17 weeks of treatment and remained stable during the entire
course of chemotherapy for 9.7 months. In parallel, Ca 19-9 serum levels, which were elevated 5-
fold at time of diagnosis, returned to normal after 16 weeks of treatment. The performance status
stabilized and intravenous alimentation could be discontinued.
Conclusion: Our experience from one patient with CC suggests, that a combination of cytotoxic
chemotherapy together with cetuximab may show promising efficacy in respect to survival and
quality of life. Therefore cetuximab, as a component of palliative chemotherapy in biliary tract
cancer, needs further evaluation in prospective randomized trials.
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Background
Most patients suffering from cholangiocarcinoma (CC)
show extensive local disease hampering curative resec-
tion. After resection local recurrence and metastatic dis-
ease often determines the overall outcome. Therefore,
treatment of these patients with potent cytotoxic chemo-
therapies is a crucial issue. In addition, patients with
resectable tumors have a high recurrence rate with a 5-year
survival rate of 9–18% for proximal peri-hepatic lesions
and 20–30% for more distal malignant manifestations
[1]. Adjuvant therapy did not improve survival rates in
context of biliary tract cancer and is therefore not advised.
The only entity of biliary tract cancer, which may profit
from adjuvant chemotherapy, might be gall bladder can-
cer [2,3]. Chemotherapy has been commonly used to
improve outcome and to control tumor progression. Dif-
ferent chemotherapeutic agents have been employed. The
results are yet limited on improved quality of life with
reduced analgesic requirement during supportive care.
Prolongation of median survival in comparison to best
supportive care remained marginal (6 months vs. 2.5
months) during palliative chemotherapy [4]. Gemcitab-
ine is a promising agent, which has shown efficacy in bil-
iary tract cancer. Gemcitabine is administered as single
agent or in combination with other cytotoxic partners.
The response rates on single agent gemcitabine range from
8 to 60 percent, depending on the cohort reported [5]. The
average study populations are limited in size with the larg-
est phase II study reporting results from 39 patients. New
targeted therapies directed against epithelial growth factor
receptor (EGFR), which is frequently overexpressed on
transformed cells, have improved outcome in other
malignant entities, predominantly colorectal cancer. As a
recent phase II study indicates, that EGFR-targeted therapy
in combination with gemcitabine might improve the out-
come in pancreatic cancer [6], we initiated an experimen-
tal course of gemcitabine in combination with EGFR
antibody (cetuximab) for a patient suffering from unre-
sectable CC.
Case presentation
Clinical presentation
A 69 Year old male presented to our clinic with abdominal
discomfort, nausea and a weight loss of 18 kg within four
months. The overall performance status was significantly
reduced (Karnofsky-Index: 70%). A palpable spleen and
tenderness of the right lower abdominal quadrant were
found during physical examination, whereas no other rel-
evant pathological findings were evident. Initial com-
puted tomography of the abdomen and thorax revealed a
hepatic mass and was indicative for peritoneal carcinoma-
tosis. The tumor was located adjacent to the gallbladder
and administration of oral contrast medium before com-
puted tomography did not show any luminal tumor of the
intestine. Without evidence for intra or extra-hepatic
cholestasis, laboratory findings during first clinical pres-
entation showed inflammatory changes (c-reactive pro-
tein: 345 mg/l, normal range < 5 mg/l) and elevated γ-
glutamyl transpeptidase serum-levels (5-fold). These find-
ings were suggestive for tumor-associated cholangitis and
were treated with wide spectrum intravenous antibiotics
(piperacillin/tazobactam).
Subsequent diagnostic mini-laparoscopy as well as
hepatic and peritoneal biopsy confirmed the diagnosis of
a CC and proved associated peritoneal carcinomatosis.
Therefore, no curative resection was applicable due to
extensive tumor disease. Histology from the peritoneal
and hepatic biopsy showed an intermediately differenti-
ated adenocarcinoma. As the immune-histochemical
staining has been negative for CK20 and intensively posi-
tive for CK7, a carcinoma from gastrointestinal origin was
excluded [7,8]. Spin cytology from aspirated ascites
showed coherent findings. Finally, a subsequent analysis
for EGFR expression confirmed a weak (1+) tissue stain-
ing. After histological diagnosis, the initiation of chemo-
therapy was delayed, as the subsequent clinical course was
complicated by obstipation and protracted bowel
obstruction-like symptoms, which finally resolved under
laxative therapy.
Past medical history
Medical history was remarkable for an insulin dependant
diabetes mellitus (type 2) for twenty years, associated dia-
betic nephropathy and polyneuropathy. Adipositas (BMI:
34.8) and hyperuricaemia completed the pre-existing
metabolic syndrome. Essential arterial hypertension and
absolute arrhythmia, secondary to atrial flutter, showed
an uncomplicated clinical course under medical treat-
ment. The patient received amlodipine, ramiprile and
torasemide as antihypertensive treatment. Digitoxin and
phenprocoumon was administered for heart rate control
and embolic prophylaxis, respectively. Facing the exten-
sive CC, phenprocoumon was discontinued and switched
to a therapeutical dose of fractionated low molecular
heparin. Insulin (10 IU/day), pravastatin and allopurinol
were further co-medications at time of first admission. An
analgesic therapy became mandatory, due to tumor-asso-
ciated pain. Analgesics were titrated to 75 mcg/h fentanyl
via a trans-dermal application system (SMAT) and oral
metamizol (3 g/day) in combination with amitryptiline
(25 mg/day), which led to sufficient pain control. Finally,
a subclavian port device was implanted to facilitate sup-
portive parenteral nutrition (1500 kcal/day) facing severe
tumor-associated anorexia.
Chemotherapy regime
Following informed consent, an experimental chemother-
apy based on gemcitabine and anti-EGFR antibody (cetux-
imab) was initiated within the fourth week (25th day) afterBMC Cancer 2006, 6:190 http://www.biomedcentral.com/1471-2407/6/190
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first clinical presentation. Chemotherapy was adminis-
tered via central venous catheter. The initiated schedule
comprised applications of gemcitabine (1000 mg/m2
bodysurface) every other week. The combination with
cetuximab, starting with a loading dose of 400 mg/m2 and
followed by a weekly maintenance dose of 250 mg/m2
bodysurface, was initiated together with the fourth gem-
citabine cycle after financial approval for its experimental
use. The patient received 20 cycles of chemotherapy for 42
weeks (i.e. 9.7 months) during the reported time period of
10.7 months since first presentation. The cumulative dose
of gemcitabine reached 31.0 g/m2 bodysurface and 14.9 g/
m2 bodysurface for cetuximab during the reported period.
Chemotherapy-related toxicity and dose-modifications
Haematological toxicities were the most relevant gemcit-
abine-related side effects observed during chemotherapy,
leading to severe leukopenia (CTC, grade 3), neutropenia
(CTC, grade 2) and thrombocytopenia (CTC, grade 3).
The haematological events required treatment with
recombinant granulocyte colony-stimulating factor (fil-
grastim, 300 mcg/day) and transfusion of platelet concen-
trates, respectively. The patient was hospitalized to
manage resulting neutropenic fever (CTC, grade 3) with
intravenous antibiotics. Each documented episode of
neutropenic fever was promoted by Staphylococcus epider-
dimis sepsis, initiated by recurrent catheter-related infec-
tions. Thus, the revision of the infected port system
abolished further recurrent catheter sepsis. Anorexia
(CTC, grade 3), nausea (CTC, grade 3), alopecia (CTC,
grade 1) and fatigue (CTC, grade 1) were other docu-
mented gemcitabine-related side effects. Toxicities caused
by cetuximab were restricted to mild rosacea (CTC, grade
1) of the head and neck region. Other dermatological tox-
icities due to cetuximab did not develop during treatment.
Severe complications under chemotherapy required hos-
pitalization for 5.3 weeks (37 days), during which com-
plete chemotherapy was paused. The second episode of
chemotherapy-induced leukopenia has led to a prolonged
dose reduction (50 percent) of gemcitabine for three sub-
sequent cycles.
Response to chemotherapy
After nine cycles of chemotherapy abdominal CT-imaging
showed a partial response, according to RECIST criteria.
The hepatic target lesion showed a reduction in diameter
of more than 30%. Additional hypervascularized non-tar-
get lesions, depicted in the hepatic arterial contrast phase,
were no longer detectable after administration of the ini-
tial chemotherapy cycles. Peritoneal enhancement, repre-
senting peritoneal carcinomatosis, vanished completely
after initiation of therapy. (Figure 1 and 2) Concordant
with the radiological observations Ca 19-9 levels, which
were elevated more than fivefold, returned to normal after
16 weeks of treatment. (Figure 3) During subsequent radi-
ological follow up, tumor remission was persisting, show-
ing ongoing stable disease for additional 26 weeks of
treatment.
Most importantly, the clinical status (Karnofsky-Index:
70–80%) stabilized during chemotherapy and did not
show any worsening until the end of follow up. Whereas
the first three cycles of gemcitabine did not affect overall
performance status significantly, tumor-associated ano-
rexia improved after six cycles of combined gemcitabine
and cetuximab. Therefore supplemental alimentation was
discontinued, which was administered within the first
four months after diagnosis. Also the initial analgesic dose
of 75 mcg/h transdermal fentanyl could be reduced by
30% to 50 mcg/h.
Conclusion
Expression of EGFR has been shown to be crucial for can-
cerogenesis in different tumor entities [9,10]. Moreover,
EGFR-positive malignancies from bilio-digestive origin
are associated with unfavourable outcome [11]. There-
fore, EGFR-targeted therapies have been introduced to
extended chemotherapeutic regimes. The fact that the
addition of anti-EGFR antibodies to cytotoxic chemother-
apy may rescue and increase response, suggests comple-
mentary anti-neoplastic mechanisms. The inhibition of
EGFR homo- or hetero-dimerisation by EGFR antibodies
interrupts cell signalling and initiates anti-neoplastic
downstream effects, which lead to phosphorylation of
tyrosine kinases. Phosphorylation of tyrosine kinases
abrogates cell cycle progression and influences cellular
adhesion, migration and differentiation [12,13]. In addi-
tion, angiogenesis is regulated by EGFR-dependant signal
cascades and is modified by inhibitory anti-EGFR anti-
bodies [14]. Despite cetuximab is not cytotoxic, subse-
quent apoptotic cell death may eventually lead to tumor
involution.
Especially results from prospective trials addressing the
response of colorectal cancer to cetuximab containing
regimes have confirmed its efficacy in clinical practice.
Second line therapies of colorectal cancer after failure of
fist-line regimes show response rates of 17–23% and an
overall survival (median) of 8.6 months [15,16]. Follow-
ing these results, cetuximab has become the first mono-
clonal antibody for 2nd line treatment of colorectal cancer,
which has been approved by the US. Food and Drug
Administration.
Even pancreatic adenocarcinoma, which is associated
with unfavourable prognosis, is sensitive to cetuximab
administration [6]. This has been shown by a phase II
trial, comprising 41 patients with unresectable pancreatic
adenocarcinoma. Patients in this trial required a con-
firmed EGFR expression and were treated with a fist-lineBMC Cancer 2006, 6:190 http://www.biomedcentral.com/1471-2407/6/190
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therapy consisting of gemcitabine (1000 mg/m2 weekly)
and cetuximab (loading dose: 400 mg/m2, maintenance
dose: 250 mg/m2). The promising results of this observa-
tion showed five patients (12.2%) who achieved a partial
response and 26 (63.4%) with stable disease. The median
time to disease progression was 3.8 months and the
median overall survival duration was 7.1 months. One-
year progression-free survival and overall survival rates
were 12% and 31.7%, respectively.
Although the extent of EGFR expression of the target
malignancy has not been associated with the overall
response rate [17,18], we performed an immune-histo-
chemical staining of the CC prior to treatment and were
Radiological follow up of hepatic tumor manifestations Figure 1
Radiological follow up of hepatic tumor manifestations. MS- CT axial: Representative nodule of the diffuse cholangi-
ocarcinoma with marked arterial phase contrast enhancement (A), declining under chemotherapy (B).
Radiological follow up of peritoneal carcinomatosis Figure 2
Radiological follow up of peritoneal carcinomatosis. MS- CT axial (contrast-enhanced, portal-venous phase): Peritoneal 
carcinomatosis (omental cake) (A), regressive under chemotherapy (B).BMC Cancer 2006, 6:190 http://www.biomedcentral.com/1471-2407/6/190
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able to confirm a positive EGFR status. Subsequent follow
up clearly showed a response by tumor reduction, which
was maintained until end of follow up. The synergistic
effect of cetuximab seems more convincing, if the reduced
gemcitabine dosage is taken into account, which was
administered every other week in contrast to a standard-
ized weekly schedule (1000 mg/m2 bodysurface). Even
more pronounced dose reductions to only 37.4% of the
standard dose were mandatory during the initial adminis-
trations of gemcitabine as single agent. Beside these prom-
ising results, cetuximab based palliative therapy was well
tolerated. Even in combination with cytotoxic regimes,
administration of cetuximab does not significantly
increase frequency and severity of chemotherapy associ-
ated toxicity. Cutaneous toxicity is predominantly
observed during cetuximab administration, while life
threatening side effects are mainly restricted to cytotoxic
drugs. In this reported case, only mild acneiforme rash
could be addressed to cetuximab, whereas severe haema-
tological and infectious complications were gemcitabine-
related.
A significant reduction of analgesic medication and the
discontinuation of parenteral nutrition have been the
most striking clinical changes, after cetuximab has been
added to the gemcitabine-based chemotherapy. As tumor-
associated pain and tumor-associated anorexia influences
individual performance status, the treatment significantly
affected quality of life. Therefore, the combination of
EGFR-specific antibodies with cytotoxic chemotherapy
backbones, such as gemcitabine, is a promising combina-
tion for palliative treatment. Further prospective trials are
mandatory to confirm the effects observed in this single
case and to discriminate gemcitabine-induced from cetux-
imab-associated response.
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